Targeting Splicing in Prostate Cancer

Area of Science:

• Molecular Biology
• Genetics
• Oncology

Background:

• Over 95% of human genes undergo alternative splicing, producing splice isoforms with diverse, often opposing, functions.
• Alternative splicing plays a critical role in the development and progression of various diseases, including cancer.

Purpose of the Study:

• To identify and discuss genes and their splice isoforms implicated in prostate cancer.
• To explore novel therapeutic strategies targeting alternative splicing in prostate cancer.

Main Methods:

• Review and analysis of scientific literature linking specific genes to prostate cancer via alternative splicing.
• Discussion of potential therapeutic modalities targeting splice isoforms and splicing machinery.

Main Results:

• Identification of key genes (VEGFA, KLF6, BCL2L2, ERG, AR) with alternative splicing linked to prostate cancer.
• Elucidation of the antagonistic functional roles of certain splice isoforms.

Conclusions:

• Targeting specific splice isoforms or the splicing machinery presents a promising avenue for novel prostate cancer therapies.
• Therapeutic approaches include small molecule inhibitors, siRNAs, and splice switching oligonucleotides.